Gold has soared to record highs with a near-50% rise this year, fuelled by inflation concerns, widening institutional and retail demand, and so‑called “gold‑plated Fomo,” prompting wealth managers and funds to raise allocations as bullion consolidates its role as a core diversifier.
The Home Office is making renewed efforts to require Apple to provide access to encrypted user data by seeking a new order that would facilitate law enforcement access to information stored on the company’s cloud services, following previous resistance from both Apple and privacy campaigners.
Starmer is rallying Labour with national symbolism and a focus on appealing to working-class voters, setting out a direct challenge to Reform while emphasising themes of renewal and left-leaning economic change.
Labour is considering the option of tax rises in the upcoming Budget, as Reeves emphasises the need for fiscal discipline in order to maintain economic stability.
Unpredictable policy changes and abrupt shifts in regulatory direction in the US are prompting international companies to reconsider their strategies, with particular concerns over new restrictions impacting investment flows, staffing, and business plans around the world.
Donald Trump has indicated he intends to pursue further political and legal action against members of the opposition party and former officials, following the indictment of the previous FBI director.
Labour mayor Andy Burnham’s plan to borrow £40 billion for Greater Manchester initiatives has unnerved investors, warning it could spark a sharp rise in gilt yields and depress sterling amid concerns about fiscal overreach.
Pimco anticipates that continued falls in inflation will enable the Bank of England to introduce deeper interest rate cuts, as slowing wage growth and the fading impact of one-off factors are expected to improve the economic outlook over the coming year.
The Eli Lilly chief executive has joined other major pharmaceutical companies in criticising the current UK drug pricing system, warning it deters investment and threatens access to new medicines.
